We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
From Apr 2019 to Apr 2024
TIDMAVO
RNS Number : 6440M
Advanced Oncotherapy PLC
01 August 2017
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company, purchased 100,000 ordinary shares of 25 pence in the Company ("Ordinary Shares") at a price of 17.75 pence per Ordinary Share.
Following this transaction, Dr Vanni now holds 1,223,946 Ordinary Shares, representing 1.51% of the Company's issued share capital.
For further information, please contact:
Advanced Oncotherapy www.avoplc.com Plc Dr. Michael Sinclair, Tel: +44 20 3617 8728 Executive Chairman Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio Bossi / David Tel: +44 20 7601 6100 Coaten Stifel Nicolaus Europe (Joint Broker) Jonathan Senior / Ben Tel: +44 20 7710 7600 Maddison Walbrook PR (Financial Tel: +44 20 7933 8780 or PR & IR) avo@walbrookpr.com Paul McManus / Anna Mob: +44 7980 541 893 / Mob: Dunphy +44 7876 741 001
About Advanced Oncotherapy plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBUGDRSSXBGRB
(END) Dow Jones Newswires
August 01, 2017 02:02 ET (06:02 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
